Evidence map›Paper›PMID 37736340›Full record

ArticleBioImpacts : BI2023

Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity.

Sanya Haiaty, Mohammad-Reza Rashidi, Maryam Akbarzadeh, Ahad Bazmany, Mostafa Mostafazadeh, Saba Nikanfar, Roya Shabkhizan, Rostam Rezaeian, Reza Rahbarghazi, Mohammad Nouri

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioImpacts : BI, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sanya HaiatyStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-1784-4926
Mohammad-Reza RashidiStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam AkbarzadehStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Ahad BazmanyDepartment of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University Of Mashhad, Mashhad, Iran.
Mostafa MostafazadehDepartment of Biochemistry and Clinical Laboratories, Tabriz University of Medical Sciences, Tabriz, Iran.
Saba NikanfarDepartment of Biochemistry and Clinical Laboratories, Tabriz University of Medical Sciences, Tabriz, Iran.
Roya ShabkhizanDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Rostam RezaeianResearch Center of Infectious Diseases and Tropical Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Reza RahbarghaziStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-3864-9166
Mohammad NouriStem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The inhibition of vascularization into tumor stroma as well as dynamic cell growth is the center of attention. Here, we aimed to examine the role of vandetanib on angiogenesis capacity of breast cancer stem cell (CSCs). Methods: MDA-MB-231 cells were exposed to different doses of vandetanib and survival rate was monitored. Stimulatory effects of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF) were evaluated in vandetanib-treated MDA-MB-231 cells. In vitro tubulogenesis capacity was studied on the Matrigel surface. The synergistic effects of vandetanib on cell survival were also assessed after PI3K and/or Wnt3a inhibition. Vascular endothelial (VE)-cadherin, matrix metalloproteinase-2 (MMP-2), -9, Wnt3a, and p-Akt/Akt ratio were measured using western blotting. Results: Vandetanib reduced survival rate in a dose-dependent manner ( Conclusion: Vandetanib suppressed vasculogenic mimicry (VM) networking through blunting stemness properties, coincided with suppression of VE-cadherin in CSCs.

Indexed as

MDA-MB-231 cellsVandetanibVasculogenic mimicryWnt3a-PI3K signaling pathways

Identifiers

PMID37736340
PMCPMC10509738
OpenAlexW4308415649

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.